China Antibody Drug Conjugates Market Size & Outlook
- Pharmaceuticals
- Oncology Drugs
- Antibody Drug Conjugates Market Outlook
- Oncology Drugs
Global Market
Related Markets
Ask Prism AI anything about the antibody drug conjugates market
Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.
China antibody drug conjugates market highlights
- The China antibody drug conjugates market generated a revenue of USD 898.6 million in 2025 and is expected to reach USD 2,297.3 million by 2033.
- The China market is expected to grow at a CAGR of 11.8% from 2026 to 2033.
- In terms of segment, breast cancer was the largest revenue generating application in 2025.
- Urothelial Carcinoma is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2025 | USD 898.6 million |
| Market revenue in 2033 | USD 2,297.3 million |
| Growth rate | 11.8% (CAGR from 2026 to 2033) |
| Largest segment | Breast cancer |
| Fastest growing segment | Urothelial Carcinoma |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Breast Cancer, Blood Cancer, Urothelial Carcinoma, Ovarian Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, China accounted for 6.2% of the global antibody drug conjugates market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,442.0 million by 2033.
China’s ADC market is expected to grow at a significant rate over the forecast period, owing to increase in availability and focus on development of ADC therapies. Chinese companies such as Reme Gen Co., Ltd., Bio-Thera Solutions, and 3SBio Group are making significant investments in ADC drug development. Reme Gen Co., Ltd.’s lead ADC drug candidate, disitamab vedotin (RC48), was the first to undergo human studies in China.
The company has already filed for NDA of this product with the NMPA for treatment of stomach cancer. The drug was granted priority review in August 2020. In 2018, Bio-Thera Solutions’ lead ADC candidate, BAT8001, entered phase 3 trial for treatment of advanced HER2-positive breast cancer.
It skipped phase 2 clinical trials and surpassed RC48 by becoming the first ADC to have entered Phase 3 studies in China. The development and subsequent approval for ADC drugs by local players is expected to be one of the major factors driving the ADC market in China.
No credit card required*
Publish Date: Nov 10, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Gilead Sciences Inc | View profile | 18,000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | www.gilead.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49,095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | www.takeda.com |
| Daiichi Sankyo Co Ltd | View profile | 17,435 | 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 | www.daiichisankyo.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
| GlaxoSmithKline Consumer Healthcare (GSK CH India) | View profile | 1001-5000 | Gurgaon, Haryana, India, Asia | india-consumer.gsk.com/ |
| ADC Therapeutics SA | View profile | 274 | Route de la Corniche 3B, Biopole, Epalinges, Switzerland, 1066 | www.adctherapeutics.com |
China Antibody Drug Conjugates Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Antibody Drug Conjugates Market Outlook will help companies and investors design strategic landscapes.
Breast Cancer was the largest segment with a revenue share of 47.85% in 2025.
Horizon Databook has segmented the China antibody drug conjugates market based on breast cancer, blood cancer, urothelial carcinoma, ovarian cancer covering the revenue growth of each sub-segment from 2021 to 2033.
China’s ADC market is expected to grow at a significant rate over the forecast period, owing to increase in availability and focus on development of ADC therapies. Chinese companies such as Reme Gen Co., Ltd., Bio-Thera Solutions, and 3SBio Group are making significant investments in ADC drug development. Reme Gen Co., Ltd.’s lead ADC drug candidate, disitamab vedotin (RC48), was the first to undergo human studies in China.
The company has already filed for NDA of this product with the NMPA for treatment of stomach cancer. The drug was granted priority review in August 2020. In 2018, Bio-Thera Solutions’ lead ADC candidate, BAT8001, entered phase 3 trial for treatment of advanced HER2-positive breast cancer.
It skipped phase 2 clinical trials and surpassed RC48 by becoming the first ADC to have entered Phase 3 studies in China. The development and subsequent approval for ADC drugs by local players is expected to be one of the major factors driving the ADC market in China.
- China Antibody Drug Conjugates Market Application Outlook (Revenue, USD Million , 2021-2033)
- Breast Cancer
- Blood Cancer
- Urothelial Carcinoma
- Ovarian Cancer
- Others
- China Antibody Drug Conjugates Market Technology Outlook (Revenue, USD Million , 2021-2033)
- Cleavable Linker
- Non-Cleavable Linker
- Others
- China Antibody Drug Conjugates Market Payload Outlook (Revenue, USD Million , 2021-2033)
- Auristatins (MMAE, MMAF)
- Maytansinoids (DM1, DM4)
- Calicheamicin Derivatives
- Topoisomerase I Inhibitors (SN-38, DXd)
- Pyrrolobenzodiazepine (PBD) Dimers
- Others
- China Antibody Drug Conjugates Market Product Outlook (Revenue, USD Million , 2021-2033)
- Kadcyla (ado-trastuzumab emtansine)
- Enhertu (trastuzumab deruxtecan)
- Trodelvy (sacituzumab govitecan)
- Adcetris (brentuximab vedotin)
- Polivy (polatuzumab vedotin)
- Others (Padcev, Tivdak, Elahere, Zynlonta, Mylotarg, Besponsa)
- China Antibody Drug Conjugates Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacy
- Specialty Pharmacy
- Others
Reasons to subscribe to Antibody Drug Conjugates Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Antibody Drug Conjugates Market Outlook databook
- Our clientele includes a mix of Antibody Drug Conjugates Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China Antibody Drug Conjugates Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into China Antibody Drug Conjugates Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
China Antibody Drug Conjugates Market, 2021-2033 (US$M)
China antibody drug conjugates market statistics, by application, 2021-2033 (US$M)
